Thursday, January 26, 2012
Max Planck cell biologists have challenged the scientific
research community to replace one of the most entrenched tools of preclinical
studies-the HeLa cell line-with stem cell lines.1 The latter, they
contend, more accurately reflect the underlying molecular complexity of healthy
and diseased tissue, but technical and economic considerations may slow stem
cells' adoption by the wider research community.
How to build
Fulmer, T. SciBX 5(4);
doi:10.1038/scibx.2012.90 Published online Jan. 26, 2012
1. Hyman, A.H. &
Simons, K. Nature 480, 34 (2011)
2. Lucey, B.P. et al. Arch. Pathol.
Lab. Med. 133, 1463-1467 (2009)
3. Bodnar, A.G. et al. Science 279, 349-352 (1998)
AND INSTITUTUTIONS MENTIONED
Cellular Dynamics International Inc., Madison, Wis.
iPierian Inc., South San Francisco, Calif.
The Johns Hopkins University, Baltimore, Md.
Max Planck Institute of Molecular Cell Biology and
Genetics, Dresden, Germany
National Institutes of Health, Bethesda, Md.
University of Texas Southwestern Medical Center, Dallas, Texas